According to the Bayesian rank probability analysis (Figure 8; Supplementary Table 6), for ESCC patients without selected PD-L1 expression, toripa-chemo is most likely to rank first in terms of OS with a cumulative probability of 57.12%. This evidence concerns the gene CD274 and esophageal squamous cell carcinoma.